Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Avalo Therapeutics, Inc.

NASDAQ: AVTX · Life Sciences · 4 alerts · CIK 1534120

Share price
$7.37Close, Nov 16
Market cap
$426M
Shares outstanding
57.82MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Avalo Therapeutics, Inc. filings on SEC EDGAR ↗

8:07 AM ET 8-K
Capital Raise

Avalo Therapeutics Capital Raise

Avalo Therapeutics entered into an at-the-market (ATM) sales agreement with Jefferies LLC to establish a program for the potential issuance and sale of up to $200 million of common stock. Simultaneously, the company terminated its existing sales agreement with TD Securities (USA) LLC (formerly TD Cowen) that had been in place since June 2025.

Counterparty
Jefferies LLC
7:08 AM ET 8-K
Financial Results

Avalo Therapeutics Financial Results

Avalo Therapeutics reported its third quarter 2026 financial results, highlighting a cash position of $462.8 million which is expected to fund operations into 2029. The company is advancing its lead candidate, abdakibart, toward a Phase 3 program in hidradenitis suppurativa with initiation planned for the first half of 2027.

“LOTUS provides a strong clinical foundation for advancing abdakibart toward registrational development in hidradenitis suppurativa. The efficacy and safety results observed across both dosing regimens, together with the potential for once-monthly administration, give us confidence in abdakibart’s potential to become an important new treatment option for patients with HS.”

Garry Neil, MD, Chief Executive Officer
7:06 AM ET 10-Q
Financial Results

Avalo Therapeutics Q3 2026 Results: Net Loss of $18.9M, Loss Narrows

Avalo Therapeutics reported its quarterly financial results for the period ended September 30, 2026, highlighting the continued clinical development of its lead immunology assets. The filing details research and development expenses, net losses, and the company's current liquidity position as it pursues key pipeline milestones.

Key figure
Net loss $18.9M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.